Diagnostic and Interventional Cardiology DAIC

Diagnostic and Interventional Cardiology (DAIC) is a magazine that reaches more than 25,000 healthcare professionals in cardiology, interventional cardiology and cath labs across the United States. These influential buying team members rely on DAIC's award-winning editorial content and comparison charts as a unique research tool for specifying, recommending and approving technology/device purchases.

The American Heart Association to enable a wide range of research with real-time data from acute care hospitals

News | Cardiogenic Shock

New Data Registry Collects Evidence in Cardiogenic Shock Patients

October 20, 2022 — Cardiogenic shock—a life threatening condition when a person’s heart can’t pump enough blood to meet ...

October 20, 2022

MedAtlas CV will transform cardiovascular care delivery and expand patient access

News | Cardiovascular Business

Atlas Healthcare Partners and MedAxiom Unveil Cardiovascular ASC Solution, MedAtlas CV

October 20, 2022 — Atlas Healthcare Partners – which specializes in developing and managing ambulatory surgery centers ...

October 20, 2022

After dedicating the last 28 years to building one of the world’s leading cardiovascular centers, Dr. Fuster will continue to advance the clinical care, research, and innovative training at Mount Sinai Heart. Image courtesy of Mount Sinai Health System

News | Cardiovascular Business

Valentin Fuster, MD, PhD, Named President of Mount Sinai Heart

October 19, 2022 — Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named ...

October 19, 2022

For men and women, the risk factors for cardiovascular disease are largely the same, an extensive global study involving University of Gothenburg researchers shows.

News | Heart Failure

Cardiovascular Disease Risks the Same in Both Sexes

October 19, 2022 — For men and women, the risk factors for cardiovascular disease are largely the same, an extensive ...

October 19, 2022

News | Heart Valve Technology

Foldax Appoints Gregory D. Casciaro as Chief Executive Officer

October 18, 2022 — Foldax, Inc. announced that medtech veteran Gregory D. Casciaro has been named Chief Executive ...

October 18, 2022

News | Heart Valve Technology

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

October 18, 2022 — The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for its ...

October 18, 2022

People with cardiovascular disease still have a high burden of risk factors for severe COVID

News | Coronavirus (COVID-19)

Smoking, Diabetes and Obesity - Not Preexisting Heart Disease - Bigger Risk of COVID-19 Death, Study Finds

October 17, 2022 — A national study suggests that risk factors for cardiovascular disease, such as age, smoking and ...

October 17, 2022

Low-cost blood pressure lowering drugs, statins and aspirin widely in the form of a single pill, also known as the polypill. McMaster University

News | Pharmaceuticals

The Polypill Could Avoid Millions of Premature Deaths, Heart Attacks and Strokes Every Year, Say Leading Cardiology Experts

October 17, 2022 — Global Health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs ...

October 17, 2022

Study data show clinically meaningful impact on quality of life and disease severity, even in the most complex patients

News | Venous Therapies

ABRE Clinical Study 36-Month Data Shows Sustained Effectiveness of Abre Venous Self-Expanding Stent System

October 14, 2022 — Medtronic, a global leader in medical technology, announced the 36-month final results from the ABRE ...

October 14, 2022

Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testinG, of Heart Failure therapies) study, announced the premature termination of the trial.

News | Cardiovascular Clinical Studies

STRONG-HF Study in Patients Admitted for Acute Heart Failure (HF) Terminated Early for Superior Efficacy

October 14, 2022 — Heart Initiative, the sponsor of the STRONG-HF (Safety, Tolerability and efficacy of Rapid ...

October 14, 2022

The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022

News | Heart Failure

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

October 13, 2022

the U.S. Patent and Trademark Office has issued to the University of Iowa Research Foundation ("UIRF") U.S. Patent No. 11,414,704 titled COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE, which is exclusively licensed to the Company from UIRF

News | Heart Failure

Cardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

October 13, 2022 — Cardio Diagnostics, Inc. , a pioneering precision cardiovascular testing company, announced that the ...

October 13, 2022

Zach Williams wanted to be a cancer researcher, but quick success in another area refocused his research on cardiovascular science. He was awarded a National Institutes of Health grant to fund his research for two years. Image courtesy of Clayton Metz/Virginia Tech.

News | Heart Failure

Virginia Tech Graduate Student Earns NIH Support to Explore Promising Heart Finding

October 13, 2022 — Zach Williams thought he’d become a cancer researcher when he joined Virginia Tech’s Translational ...

October 13, 2022

Videos | TCT

VIDEO: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

October 13, 2022

The Delphi study results show Philips’ integrated echocardiography solution provides the tools required for baseline risk stratification and monitoring of cardio-oncology patients as recommended by the latest European Society of Cardiology (ESC) guidelines

News | Heart Failure

Panel of Experts Highlights Clinical and Operational Benefits of Philips’ Integrated Echocardiography Solution

October 12, 2022 — Following the recent European Society of Cardiology (ESC) Congress in Barcelona, Spain last month, ...

October 12, 2022